Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study

Table 4 Tumor responses

Response	All	Squamous cell carcinoma	Adenocarcinoma
N (missing)	43 (6)	29 (5)	14 (1)
BOR, n (%)
CR	0	0	0
PR	11 (25.6%)	11 (37.9%)	0
SD	31 (72.1%)	18 (62.1%)	13 (92.9%)
PD	1 (2.3%)	0	1 (7.1%)
ORR, n (%)	11 (25.6%)	11 (37.9%)	0
DCR, n (%)	42 (97.7%)	29 (100.0%)	13 (92.9%)

BOR, best objective response; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate

ISSN: 1471-2407